IGF Inhibitors
1 drugsAbout IGF
Insulin-like Growth Factor (IGF) signaling regulates cell growth, differentiation, and survival. Dysregulation of the IGF pathway, involving ligands, receptors, and intracellular signaling cascades, can contribute to tumor development.
IGF is a therapeutic target in oncology, though no genetic evidence directly links IGF to specific diseases in this dataset. Its importance is underscored by the presence of at least one FDA-approved drug modulating this pathway.
IGF is targeted by one FDA-approved drug, Gefitinib, a small molecule for oncology indications. Cipla is the only company with an approved drug targeting IGF.
Top IGF Drugs
Cipla is the only company with an approved drug targeting IGF.
The market is not competitive, suggesting an opportunity for new entrants.
IGF Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets IGF, using small molecule modality.
Exploring other modalities like antibodies or fusion proteins could provide a competitive advantage.
IGF Clinical Trials 71 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IGF. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 13 | 1 | 3 | 93% |
| Phase 2 | 34 | 23 | 6 | 4 | 79% |
| Phase 3 | 17 | 10 | 3 | 4 | 77% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
IGF Drug Approval Timeline (2022 - 2022)
The first and most recent drug approval for IGF was Gefitinib in 2022.
Recent approval suggests renewed interest, but a single approval indicates potential saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 52 (21 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IGF. A trial counts if an approved drug acting on IGF is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.